Vijayakrishna Gadi, MD, PhD, provides an overview of recent advancements in the treatment of HER2+ metastatic breast cancer with special consideration for challenges in the management of patients with CNS metastases.
July 1st 2022
Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.
An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.
July 8th 2022
Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.
A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.